Generic marketing is conceptual.

FORBES: The Dangerous Seduction of the Lifetime Value (LTV) Formula

Teva the largest generic pharmaceutical company in the world, marketing about 400 generic medications and 50 brand-name drugs, with approximately 180 new generics awaiting FDA approval.

FORBES: Vanguard Health Care Fund's Latest Purchase: GMCR,TEVA, RHHBY, MDRX

And both the large companies and the generic makers say the marketing of generics often is hastened by these deals.

NPR: Court: Can Drug Companies Pay To Delay Generics?

Schering has argued that it has patents that should prevent generic drug companies from marketing their own versions of Claritin until 2004.

FORBES: Claritin Will Be Sold Without A Prescription

The Petitioners asked the Court to review whether federal antitrust laws prohibit the settlement of patent litigation between a branded drug maker and a generic drug company which include a financial incentive for the generic company to hold off marketing its product for a time period.

FORBES: Campaign Against 'Pay-for-Delay' Drug Patent Settlements Suffers Setback at Supreme Court

Unlike many internet-based businesses that have a marketing strategy to capture generic search traffic, my business is meant to be the basis for a unique brand.

FORBES: How Do You Pick A Name For Your Business?

The complementary assets tend to be generic, between the server farms, marketing and advertiser relationships.

FORBES: Facebook Valuation: We Don't Know What We Don't Know

But federal officials counter that such deals add billions to the drug bills of American patients and taxpayers, compared to what would happen if the generic companies won the lawsuits and could begin marketing right away.

NPR: Court: Can Drug Companies Pay To Delay Generics?

That means that a cause marketing message can move from a very generic statement--i.e.

FORBES: Magazine Article

With billions of dollars at stake and neither company certain how it might fare in court, a brand-name manufacturer might prefer to pay its potential competitor substantial compensation to delay its generic drug and the generic maker might welcome a hefty payoff rather than face the uncertainties of litigation and marketing.

FORBES: The Times Reproduces The FTC's Flawed Position On Drug Patent Settlements